" Entheon Biomedical (CSE:ENBI) subsidiary enters agreement with Psychedelics Today

Entheon Biomedical Corp. (ENBI) has entered into an agreement with Psychedelics Today, LLC to drive awareness for the Psychedelics Genetic Test Kit.
Optimi Health Corp. - Chief Science Officer, Justin Kirkland

" Optimi Health (CSE:OPTI) submits psilocybin formulation for patent

Optimi Health Corp. (OPTI) has submitted a second patent for a two-part processing method involving the extraction and delivery of psilocybin active components.

" PharmaDrug (CSE:PHRX) director resigns from board

PharmaDrug Inc. (PHRX) has announced the resignation of Robert Schwartz from the board of directors.

" Core One Labs (CSE:COOL) receives Health Canada approval for DMT

Health Canada has authorized Core One (COOL) to add DMT to its Controlled Drugs and Substances Act Dealer’s License.
The Market Herald Video

" Mindset Pharma (CSE:MSET) and the McQuade Center partner to develop psychedelic medicines

The McQuade Center (MSRD) and Mindset Pharma (MSET) have announced a collaboration to support the development of psychedelic medicines.

" Core One Labs (CSE:COOL) acquires New Path Laboratories

Core One (COOL) has acquired New Path Laboratories, a developer of functional mushroom health products.

" Entheon Biomedical (CSE:ENBI) psychedelics genetic test now available

Entheon Biomedical Corp.’s (ENBI) expanded psychedelics genetic testing panel is now available for sale in Canada and the United States.

" Lobe Sciences (CSE:LOBE) announces publication of PCT patent application

Lobe Sciences’ (LOBE) patent-pending therapeutic regimen designed for treating mTBI and PTSD has been published by the World Intellectual Property Organization.
Psyched Wellness - CEO and Director, Jeff Stevens.

" Psyched Wellness (CSE:PSYC) details path to U.S. market for AME-1 products

Psyched Wellness (PSYC) plans to launch its Amanita Muscaria products in the U.S. in Q2 2022.

" Canbud Distribution (CSE:CBDX) enters agreement to acquire Steep Hill Inc.

Canbud Distribution Corp. (CBDX) has entered a triangular merger agreement with Steep Hill, Inc., and Canbud Merger Sub Inc.
Red Light Holland - Director and CEO, Todd Shapiro (right).

" Red Light Holland (CSE:TRIP) expands footprint in Q2

Red Light Holland (TRIP) has reported Q2 results highlighted by a 64-per-cent increase in gross profit from Q1.

" Psyence Group (CSE:PSYG) to speak at the annual Global Wellness Summit

Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit.
Levitee Labs - CEO, Pouya Farmand.

" Levitee Labs (CSE:LVT) to acquire specialty addiction pharmacies in B.C.

Levitee Labs (LVT) has signed an LOI to acquire a chain of specialty addiction pharmacies in B.C.

" PharmaDrug (CSE:PHRX) advances psychedelics program to treat eye diseases

PharmaDrug Inc. (PHRX) announced Terasaki Institute for Biomedical Innovation (TIBI) will begin in vitro studies on a short-list of DMT analogue molecules.
The Market Herald Video

" Psyched Wellness announces the Amanita Muscaria mushroom has been added to the Natural Health Products Ingredients Database (NHPID) of Canada

Psyched Wellness (PSYC) announced that the Amanita Muscaria mushroom has been added to the Natural Health Products Ingredients Database (NHPID) of Canada.
The Market Herald Video

" Filament Health (NEO:FH) receives FDA authorization for psychedelic clinical trial

Filament Health (NEO: FH) has received FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances.

" Market research by Red Light Holland (CSE:TRIP) reveals a potential billion-dollar micro-dosing market

Market research by Red Light Holland (TRIP) reveals an estimated US$1 billion micro-dosing services market in Oregon.

" Field Trip Health (TSX:FTRP) schedules Q2 financial results conference call

Field Trip Health (FTRP) will release financial results for the fiscal second quarter ended September 30, 2021, after market close on November 15.

" Marvel Biosciences (TSXV:MRVL) developing novel non-hallucinogenic neuroplastic promoting compounds

Marvel Biosciences (MRVL) has launched a program to identify and develop agents that promote neuroplasticity without the risks or side effects of psychedelics.